BioCon Limited
20th KM Hosur Road
Electronics City
Bangalore
560 100
Tel: 90-80-2808-2808
Fax: 91-80-2852-3423
Website: http://biocon.com/
Email: contact.us@biocon.com
69 articles about BioCon Limited
-
Haselmeier GmbH Announces the Launch Of INSUPen® EZ In India By BioCon Limited
10/27/2014
-
BioCon Limited Collaborates With Advaxis, Inc. For "ADXS-HPV" A Novel Cancer Immunotherapy
1/22/2014
-
BioCon Limited Hits Roche First, Set To Launch Biosimilar Of Breast Cancer Drug Herceptin
1/21/2014
-
Mylan Inc.-BioCon Limited Receive First Indian Biosimilar Regulatory Approval For Herceptin®
11/26/2013
-
BioCon Limited Partners With CytoSorbents, Inc. to Market CytoSorb® - A "First-in-Class" Therapy for Sepsis Management
9/16/2013
-
Mylan Inc. Ties Up With BioCon Limited for Insulin Marketing
2/14/2013
-
BioCon Limited, Bristol-Myers Squibb Company Sign Pact for Experimental Oral Insulin Drug
11/16/2012
-
BioCon Limited to Sell 7.69% of Research Unit to GE Capital for $23 Million
10/31/2012
-
BioCon Limited Close to Oral Insulin Deal With Bristol-Myers Squibb Company
7/27/2012
-
BioCon Limited Opens Biologics Research Center; Will Hire 300 Scientists
4/6/2012
-
BioCon Limited Plunges After Pfizer Inc. Scraps $350 Million Insulin Pact
3/14/2012
-
India's BioCon Limited Sees Oral Insulin Partner by March
11/23/2011
-
BioCon Limited Launches Haselmeier's Insulin Pen in India
11/22/2011
-
BioCon Limited Arm Inks Pact for Clinical Research with US Firm
8/22/2011
-
Bristol-Myers Squibb Company, Sanofi (France) in Race for Drug Marketing Pact with BioCon Limited; Sources Say BioCon Oral Insulin Drug Could be Worth $1 Billion to Suitors
6/14/2011
-
BioCon Limited to Sell Stake in German Unit, AxiCorp for $59.37 Million
4/28/2011
-
BioCon Limited Experimental Insulin Drug Fails to Meet Main Goal in Patient Trial
1/11/2011
-
BioCon Limited, Pfizer Inc. In Potential $350 Million Insulin Licensing Deal
10/19/2010
-
Optimer Pharmaceuticals, Inc. and BioCon Limited Announce Manufacturing and Supply Agreement for Fidaxomicin
5/24/2010
-
Amylin Pharmaceuticals, Inc. and BioCon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid Program will Focus on the Potential Treatment of Diabetes
9/11/2009